[go: up one dir, main page]

WO1992007564A3 - Method of treating demyelinating disease - Google Patents

Method of treating demyelinating disease Download PDF

Info

Publication number
WO1992007564A3
WO1992007564A3 PCT/GB1991/001890 GB9101890W WO9207564A3 WO 1992007564 A3 WO1992007564 A3 WO 1992007564A3 GB 9101890 W GB9101890 W GB 9101890W WO 9207564 A3 WO9207564 A3 WO 9207564A3
Authority
WO
WIPO (PCT)
Prior art keywords
demyelinating disease
treating demyelinating
treating
azidothymidine
nimodipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1991/001890
Other languages
French (fr)
Other versions
WO1992007564A2 (en
Inventor
David Walter Barry
John Frederick Reinhard Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909023600A external-priority patent/GB9023600D0/en
Priority claimed from GB909023607A external-priority patent/GB9023607D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Priority to JP3517138A priority Critical patent/JPH06502155A/en
Publication of WO1992007564A2 publication Critical patent/WO1992007564A2/en
Publication of WO1992007564A3 publication Critical patent/WO1992007564A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A calcium antagonist especially nimodipine, is used for the treatment of demyelinating diseases such as multiple sclerosis. It may be used in combination with an antiviral compound which is active against retroviruses, such as azidothymidine.
PCT/GB1991/001890 1990-10-30 1991-10-29 Method of treating demyelinating disease Ceased WO1992007564A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3517138A JPH06502155A (en) 1990-10-30 1991-10-29 How to treat demyelinating diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9023607-6 1990-10-30
GB909023600A GB9023600D0 (en) 1990-10-30 1990-10-30 Method of treating demyelinating disease
GB909023607A GB9023607D0 (en) 1990-10-30 1990-10-30 Method of treating demyelinating disease
GB9023600-1 1990-10-30

Publications (2)

Publication Number Publication Date
WO1992007564A2 WO1992007564A2 (en) 1992-05-14
WO1992007564A3 true WO1992007564A3 (en) 1992-06-25

Family

ID=26297869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/001890 Ceased WO1992007564A2 (en) 1990-10-30 1991-10-29 Method of treating demyelinating disease

Country Status (3)

Country Link
EP (1) EP0555302A1 (en)
JP (1) JPH06502155A (en)
WO (1) WO1992007564A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203857D0 (en) * 1992-12-22 1992-12-22 Astra Ab USE OF AN ENANTIOMERIC DIHYDROPYRIDINE
WO2001087280A2 (en) * 2000-05-15 2001-11-22 Bayer Aktiengesellschaft Means for treating attacks of auto-immune diseases
US6455553B1 (en) * 2000-10-03 2002-09-24 Albert Einstein College Of Medicine Of Yeshiva University Method for treating a demyelinating condition
US7470718B2 (en) 2000-10-03 2008-12-30 Albert Einstein College Of Medicine Of Yeshiva University Method for treating a demyelinating condition
GB0309509D0 (en) * 2003-04-25 2003-06-04 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3868125D1 (en) * 1987-04-24 1992-03-12 Wellcome Found ANTIVIRAL MIXTURES.
GB8822546D0 (en) * 1988-09-26 1988-11-02 Wellcome Found Antiviral combinations
SE464168B (en) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg ANTIVIRAL COMPOSITION CONSISTING OF A 3'-FLUORO-2 ', 3'-DIDEOXYNUCLEOSIDE COMPOUND AND AND 2', 3'-DIDEOXYNUCLEOSIDE COMPOUND (EXAMPLE AZT)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BREUER A.C. ET AL.: "Fast axonal transport alterations in amyotrophic lateral sclerosis (ALS) and in parathyroid hormone (PTH)-treated axons", CELL MOTILITY AND TE CYTOSKELETON, ALAN R. LISS, INC., vol. 10, no. 1-2, 1988, pages 321 - 330 *
EL-FAWAL H.A.N. ET AL.: "Effect of verapamil on organophosphorus-induced delayed neuropathy in hens", TOXICOL. APPL. PHARMACOL., ACADEMIC PRESS, INC., vol. 97, no. 3, 1989, pages 500 - 511, XP024883472, DOI: doi:10.1016/0041-008X(89)90255-X *
GILMORE R.L. ET AL.: "Verapamil-induced changes in central conduction in patients with multiple sclerosis", JOURNAL OF NEUROLOGY, NEUROSURGERY, AND PSYCHIATRY, vol. 48, no. 11, November 1985 (1985-11-01), pages 1140 - 1146, XP002091417 *
KOMOLY S. ET AL.: "Multiple sclerosis: failure of treatment with verapamil in a pilot trial", JOURNAL OF NEUROLOGY, SPRINGER-VERLAG, vol. 233, no. 1, 1986, pages 59 - 60 *
KOZLOUSKY V.L. ET AL.: "Anticalcium drugs prevent the neurodegenerative effect of quinolinic acid", FARMAKOL. TOKSIKOL., vol. 53, March 1990 (1990-03-01), pages 27 - 29 *
See also references of EP0555302A1 *
WEISS J.H. ET AL.: "The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity", SCIENCE, vol. 247, 23 March 1990 (1990-03-23), pages 321 - 330 *
YANAGISAWA K. ET AL.: "Degradation of myelin basic protein by calcium-activated neutral protease (CANP) in human brain and inhibition by E-64 analogue", NEUROCHEM. RES., PLENUM PUBLISHING CORP., vol. 8, no. 10, 1983, pages 1285 - 1293, XP002091414, DOI: doi:10.1007/BF00963998 *

Also Published As

Publication number Publication date
EP0555302A1 (en) 1993-08-18
WO1992007564A2 (en) 1992-05-14
JPH06502155A (en) 1994-03-10

Similar Documents

Publication Publication Date Title
CA2213339A1 (en) Method of treating adenosine depletion
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
CA2140106A1 (en) Method of treating hyperproliferative vascular disease
NL300174I2 (en) Use of venlafaxine or an aryloxypropanamine compound for the preparation of a medicament for the treatment of incontinence.
MY140557A (en) Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
CA2160366A1 (en) Risperidone pamoate
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
MX9602683A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
CA2024188A1 (en) Method of treating premature ejaculation using sertraline
MX9605023A (en) Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
AU1808488A (en) Compounds for the treatment of alzheimer's disease
TW279865B (en)
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
WO1997009976A3 (en) Method of reducing neurotoxic injury with zinc chelators
UA19782A (en) Process for preparation of bicyclic esters or pharmaceutically acceptable salts thereof
CA2264063A1 (en) Cryptophycin compounds
CA2176298A1 (en) A single high dose fluoroquinolone treatment
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
WO1992007564A3 (en) Method of treating demyelinating disease
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
AU4434389A (en) Aqueous oral pharmaceutical preparation of diclofenac
CA2030346A1 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991918867

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991918867

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991918867

Country of ref document: EP